title: Diabetic macular edema: new trends in management.
abstract: The treatment of diabetic macular edema may be evolving from a laser ablative approach into a pharmacotherapeutic approach. The exponential growth that has occurred over the past decade in the retinal pharmacotherapy field has led to the development of several pharmacotherapies for retinal vascular diseases such as diabetic macular edema. Many of these agents, in the form of intravitreal injections or sustained delivery devices, have already undergone clinical trial testing for safety and efficacy and many others are currently being similarly evaluated. Some of these agents have proven to be more efficacious than traditional laser therapy, and it is possible that traditional laser therapy for diabetic macular edema may be abandoned altogether in the near future, especially with the introduction of the micropulse laser. However, more research and experience is still needed in order to determine the best treatment agent or combination of therapeutic modalities, as well as the best treatment regimen for a given patient. In this article, we briefly review the major new developments in the field of diabetic macular edema treatment. In addition, we touch on some of the promising forthcoming therapies.
authors.affiliation: Vitroretinal Division, King Khaled Eye Specialist Hospital, PO Box 7191, Riyadh 11462, Saudi Arabia.
authors.forename: Hanan
authors.initials: H
authors.lastname: Al Shamsi
authors.forename: Nicola G
authors.initials: NG
authors.lastname: Ghazi
mesh_terms: D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D003930:Diabetic Retinopathy / Q000473:pathology / Q000628:therapy*; D019468:Disease Management; D006801:Humans; D058449:Intravitreal Injections; D017075:Laser Coagulation / Q000639:trends; D008269:Macular Edema / Q000473:pathology / Q000628:therapy*; D000069579:Ranibizumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab